Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biovitrum and Syntonix Pharmaceuticals, a subsidiary of Biogen/Idec, have initiated a Phase I/IIa open-label, dose escalation study of a long-acting, recombinant Factor IXFc protein in patients with hemophilia B.
Subscribe to our email newsletter
The study is ongoing at clinics in the US and will assess the safety, tolerability and pharmacokinetics of Factor IXFc (FIXFc) in this patient population.
This FIXFc compound, which preclinical studies have shown to have an extended half-life, could enable effective treatment with less frequent injections for both prophylaxis and on-demand therapy in hemophilia B.
Martin Nicklasson, CEO of Biovitrum, said: “We are excited about developing FIXFc together with Syntonix since hemophilia is a prioritized therapeutic and business area within Biovitrum. In addition, we are developing a recombinant Factor VIIIFc hemophilia product with Syntonix.”